Clinical Trial Update: Ondansetron Versus Aprepitant Plus Ondansetron for Emesis [Phase 2]

View source ↗

Summary

Phase 2 trial comparing ondansetron alone versus aprepitant plus ondansetron for prevention of emesis in patients with hematologic diseases, including acute mye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Aprepitant (aprepitant)
• Ondansetron (ondansetron)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematologic Diseases, Acute Myelogenous Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2014-01-13